Prevention of Invasive Pneumococcal Disease (IPD)
More details
Hide details
2nd Pulmonary Department, “ATTIKON” University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece
Pulmonary Medicine Department, General Hospital of Pireaus, Pireaus , Greece
Associate Professor, Department of Critical Care, “Attikon” University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece
George Dimopoulos   

1 Rimini street, 12462 Haidari, Athens, Greece
Pneumon 2017;30(1):32–40
Streptococcus pneumoniae consists of a major cause of community-acquired pneumonia in the elderly, resulting in considerable morbidity and mortality worldwide. Although pneumococcal community-acquired pneumonia presents usually as non-bacteremic disease, invasive pneumococcal disease (IPD) concerns infection of normally sterile sites, such as blood or cerebral fluid. The risk for Invasive Pneumococcal Disease increases in particular groups of patients, including hematologic malignancies, infection with human immu-nodeficiency virus (HIV), asplenia - functional or anatomic, chronic diseases and extreme ages (65 years old). The prevention against IPD is achieved by vaccines against Streptococcus pneumoniae. Today, there are two available types of vaccines, the polysaccharide pneumonococcus vaccine (PPSV23 and the pneumonococcus con-jugated vaccine (PCV13).
IPD: Invasive pneumococcal disease, PPSV23: Pneumococcal polysaccharide vaccine, PCV13: Pneumococcal conjugate vaccine
GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and causespecific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015; 385:117–71.
Centers for Disease Control and Prevention. Pneumococcal disease. In: Atkinson W, et al, eds. Epidemiology and Prevention of Vaccine-Preventable Diseases. 12th ed., second printing. Washington, DC: Public Health Foundation; 2012:233–48. Accessed March 2015.
World Health Organization. Available from: Accessed March 2015.
Bonten Μ et al. Polysaccharide Conjugate Vaccine against Pneumococcal Pneumonia in Adults. N Engl J Med 2015; 372:1114-25.
Rozenbaum MH, Pechlivanoglou P, van der Werf TS, Lo-Ten-Foe JR, Postma MJ, Hak E. The role of Streptococcus pneumoniae in community-acquired pneumonia among adults in Europe: a meta-analysis. Eur J ClinMicrobiol Infect Dis 2013; 32:305-16.
World Health Organization. Pneumococcal conjugate vaccine for childhood immunization--WHO position paper. Wkly Epidemiol Rec 2007; 82:93–104.
Said MA, Johnson HL, Nonyane BA, et al. Estimating the burden of pneumococcal pneumonia among adults: a systematic review and meta-analysis of diagnostic techniques. PLoS One 2013;8:e60273-e60273.
Sjostrom K, Spindler C, Ortqvist A, et al. Clonal and capsular types decide whether pneumococci will act as a primary or opportunistic pathogen. Clin Infect Dis 2006; 42:451–9.
Sandgren A, Sjostrom K, Olsson-Liljequist B, et al. Effect of clonal and serotype-specific properties on the invasive capacity of Streptococcus pneumoniae. J Infect Dis 2004; 189:785–96.
Sandgren A, Albiger B, Orihuela CJ et al. Virulence in mice of pneumococcal clonal types with known invasive disease potential in humans. J Infect Dis 2005;192:791–800.
Harboe ZB, Thomsen RW, Riis A, et al. Pneumococcal serotypes and mortality following invasive pneumococcal disease: a population-based cohort study. PLoS Med 2009; 6: e1000081.
CDC. Active Bacterial Core surveillance. Available at:
Van Hoek AJ, Andrews N, Waight PA, et al. The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England. J Infect 2012;65:17–24.
Klemets P, Lyytikäinen O, Ruutu P, Ollgren J, Nuorti JP. Invasive pneumococcal infections among persons with and without underlying medical conditions: Implications for prevention strategies. BMC Infect Dis 2008;8:96.
Shea KM, Edelsberg J, Weycker D, Farkouh RA, Strutton DR, Pelton SI. Rates of pneumococcal disease in adults with chronic medical conditions. Open Forum Infect Dis 2014; 1:ofu024.
Siegrist C-A. Vaccine immunology. In Plotkin SA, Orenstein WA, Offit PA. Vaccines, 5th ed. China: Saunders, 2008:17–36.
Pollard AJ, Perrett KP, Beverley PC. Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Nat Rev Immunol 2009; 9:213-20.
Waight PA, Andrews NJ, Ladhani SN, Sheppard CL, Slack MP, Miller E. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study. Lancet Infect Dis 2015; 15:535-43.
Greek pneumococcal vaccination recommendations. Available from: .
Jackson LA, Gurtman A, van Cleeff M, et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults. Vaccine 2013; 31:3577–84.
Jackson LA, Gurtman A, Rice K, et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine 2013;31:3585–93.
Greenberg RN, Gurtman A, Frenck RW, et al. Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naïve adults 60-64 years of age. Vaccine 2014; 25;32:2364-74.
Whitney CG, Farley MM, Hadler J, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003;348:1737–46.
Torres A, Peetermans WE, Viegi G, Blasi F. Risk factors for community-acquired pneumonia in adults in Europe: a literature review. Thorax 2013; 68:1057-65.